The Impact of Achieving Sustained Viral Response with Direct Antiviral Agents in in HCV/HIV Co-infected Patients.
Rattachement africain : il. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) affects approximately 2.2 million people globally and is associated with accelerated liver disease progression, increased morbidity, and reduced quality of life (QoL). While direct-acting antivirals (DAAs) have revolutionized HCV treatment with high cure rates, evidence of their long-term impact on liver-related QoL and associated metabolic or immunologic shifts in HIV/HCV co-infected populations remains limited. OBJECTIVES: To evaluate the effect of achieving sustained virologic response (SVR) with DAAs on long-term QoL in HIV/HCV co-infected patients and to examine associated changes in CD4 count, kidney function, and glucose levels. METHODS: This retrospective observational study was conducted at the Rambam Health Care Campus, between 2015 and 2019. We collected demographic, clinical, and laboratory data from all patients with HIV/HCV co-infection. QoL was evaluated for at least 6 months after the end of treatment. Metabolic variables were collected before and after treatment to test the effects of treatment. RESULTS: All 70 patients in the cohort achieved SVR. Successful treatment with DAAs resulted in a significant decrease in liver enzymes and globulin levels, and a substantial increase in CD4. A significant improvement in QoL after treatment was noticed in both sexes, regardless of liver fibrosis stage. FIB-4 calculations 6 months and 1 year after the end of therapy showed improved fibrosis levels after SVR. CONCLUSIONS: The use of DAAs in HCV/HIV co-infected patients has improved the long-term QoL, metabolic factors, and fibrosis stage.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
Technion – Israel Institute of Technology pays non établi dans la noticeUniversité ou école supérieure
-
Rambam Health Care Campus pays non établi dans la noticeÉtablissement de santé
-
Hillel Yaffe Medical Center pays non établi dans la noticeÉtablissement de santé
-
Rappaport Family Institute for Research in the Medical Sciences pays non établi dans la noticeStructure de recherche
-
Bar-Ilan University pays non établi dans la noticeUniversité ou école supérieure
-
Nazareth Hospital EMMS pays non établi dans la noticeÉtablissement de santé
-
Clalit Health Services pays non établi dans la noticeÉtablissement de santé
-
Rappaport Faculty of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Azrieli Faculty of Medicine Israel pays non établi dans la noticeUniversité ou école supérieure
Technion – Israel Institute of Technology, Rambam Health Care Campus et Hillel Yaffe Medical Center, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.